weblink: http://www.gtcbio.com/conference/diabetes-drug-discovery-and-development-overview?utm_source=post+conference&utm_medium=website&utm_campaign=diabetesdd

Come and join diabetes experts at GTC’s 7th Diabetes Drug Discovery and Development Conference on April 23-25, 2014 in Cambridge, MA and hear key thought-leader's opinions on the next block-buster drug target for T1DM and T2DM and discuss how FDA guidance affects approaches to developing new medications.

The conference is part of GTC's annual Diabetes Summit which includes two co-located conferences:

7th Diabetes Drug Discovery and Development

4th Diabetes Partnering and Deal-Making

GTC's Drug Discovery and Development conference will bring together the leading experts on diabetes from academia, government, small/medium size biotech, big pharma and healthcare organizations to discuss research on various novel targets, programs in developments, regulatory guidance and other relevant insights that can help guests advance their own research.

Below is the preliminary program. For further detailed information, follow the links below:

To view the 2014 detailed agenda, click here.

To view the 2014 speaker list, click here.

2014 PROGRAM AT A GLANCE

April 23, 2014

General Session

Joint sessions with Diabetes Summit and 2014 Stem Cell Summit

Topics:

I. Cell Therapy and Diabetes - Stem Cell Research in the Diabetes Space

II. Cell Therapy Commercialization Model

Panel Discussions:

I. Acquisitions & Collaborative Environment in the Diabetes Regenerative Field

Conference I:

4th Diabetes Partnering and Deal-Making

Conference II:

7th Diabetes Drug Discovery and Development

April 24-25, 2014

Plenary Keynote Session

• Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi

• Hans-Juergen Woerle, Vice President and Head of Therapeutic Area Metabolism, Boehringer Ingelheim

• Steven E. Nissen, Chairman of Cardiovascular Medicine, Cleveland Clinic Foundation

Panel Discussion: Type 1 Diabetes: "The New Honeymoon that Last Decades" - Clinical trial opportunities and the new diverse type 1 diabetic population - can we more accurately predict complications?

Participants:

Denise Faustman, Harvard Medical School

Deneen Vojta, United Healthcare Services

Corinth Auld, Mercodia

Richard Oram, Exeter

Diabetes Partnering and Deal-Making

Continued Diabetes Drug Discovery and Development

Continued

Sessions:

I. Innovative Partnering & Licensing Strategies

II. Partnering Opportunities in Diabetes Drug Development

III. Current Trends & Recent Deals

Panel Discussions:

I. Wining Strategies in Partnering & Deal-Making

II. Partnering with Non-Profits

III. Finding the Middle Ground in Big Pharma and Biotech Partnerships

IV. Partnering with Academia

V. Investment Opportunities in the Diabetes Space

VI. Strategies for Entry into Emerging Markets

VII. Evolving Landscape of the Insulin Market

For detailed agenda & participants click here

Sessions:

I. New Therapeutic Targets for Diabetes

II. Combination Therapy

III. Clinical Drug Development in Diabetes

Part 1: Type 1 Diabetes

Part 2: Type 2 Diabetes

IV. Advances in Obesity Drug Development

V. Diabetic Complications

Panel Discussion:

I. Beyond HbA1c – Are there Better Endpoints for Clinical Trials?

II. Med-Tech Advances for the Treatment of Diabetes

For detailed agenda & participants click here

The conference will run parallel with the 4th Diabetes Partnering and Deal Making conference.

Sign up for the summit pass to have access to both conferences of the summit. Or bring a team of 3 for the price of 2 by registering with the coupon code rcdvb!

We look forward to seeing you at the conference!

Best regards,

2014 Conference Advisory Committee